Loading clinical trials...
Loading clinical trials...
The primary objectives of this study are to determine the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 12 wee...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Gilead Sciences
NCT06718530 · Hepatitis C Virus Infection
NCT05361603 · Hepatitis C, Transmission, Intravenous Drug Abuser, and more
NCT05975216 · Hepatitis C Virus Infection
NCT05071261 · Hepatitis C Virus Infection
NCT05906459 · Hepatitis C Virus Infection
Ruane Clinical Research Group Inc.
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
Stanford Hospital and Clinics
Palo Alto, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions